Use access key #2 to skip to page content.

portefeuille (99.60)

Ellipsis

Recs

9

October 09, 2009 – Comments (13)

On 09/08/09 and 09/09/09 I made a list of my "favourite" stocks (see comments #29,33,34 here).

-------------------------------------------------------------

#6) On September 15, 2009 at 9:17 AM, portefeuille (99.99) wrote:

add LXRX to my "favourites" list.

so the list is now

ATPG, BAS.DE, BAY.DE, CDE, CRME, DAI, EMC, FACT, FMCN, GLW, HL, KSB3.DE, LNUX, LXRX, PAH3.DE, QGEN, REP, RHIE, SA, SQNM, UCG.MI, VMW, VOW3.DE, YAR.OL.

-------------------------------------------------------------

(from comment #6 here)

 

performance update

ATPG, ATP Oil & Gas Corp., $14.75 -> $19.02.

BAS.DE, BASF SE, 36.12 EUR -> 37.47 EUR.

BAY.DE, Bayer AG, 44.26 EUR -> 47.71 EUR.

CDE, Coeur d`Alene Mines Corp., $19.18 -> $23.04.

CRME, Cardiome Pharma Corp., $4.50 -> $4.50.

DAI, Daimler AG, 31.97 EUR -> 34.51 EUR.

EMC, EMC Corp., $16.25 -> $17.80.

FACT, Facet Biotech Corp., $16.09 -> $17.36.

FMCN, Focus Media Holding Ltd., $9.70 -> $11.89.

GLW, Corning Inc., $15.36 -> $15.48.

HL, Hecla Mining Co., $3.85 -> $5.02.

KSB3.DE, KSB AG preferred, 389.00 EUR -> 441.00 EUR.

LNUX, SourceForge Inc., $1.29 -> $1.29.

LXRX, Lexicon Pharmaceuticals Inc., $2.09 -> $1.77.

PAH3.DE, Porsche Automobil Holding SE preferrred, 50.71 EUR -> 58.70 EUR.

QGEN, Qiagen NV, 14.45 EUR -> 14.32 EUR.

REP, Repsol YPF SA, 17.38 EUR -> 18.51 EUR.

RHIE, RHI Entertainment Inc., $3.13 -> $2.87.

SA, Seabridge Gold Inc., $30.90 -> $28.33.

SQNM, Sequenom Inc., $5.83 -> $3.34.

UCG.MI, Unicredit SpA, 2.55 EUR -> 2.69 EUR.

VMW, VMware Inc., $37.72 -> $42.28.

VOW3.DE,Volkswagen AG preferred, 64.52 EUR -> 81.72 EUR.

YARN.OL, Yara International ASA, ca. 183.00 NOK -> 188.90 NOK.

13 Comments – Post Your Own

#1) On October 09, 2009 at 2:22 AM, portefeuille (99.60) wrote:

some stocks I am currently holding or planning to buy.

Aixtron (AIXG), Allgeier (AEI.DE), ATP Oil & Gas (ATPG), Banco Santander (STD), BASF (BAS.DE), Bayer (BAY.DE), Cardiome (CRME), Coeur d'Alene Mines (CDE), Commtouch (CTCH), Daimler (DAI.DE), Deutsche Bank (DB), EMC (EMC), Erste Group (EBS.VI), Facet Biotech (FACT), Gazprom (OGZPY.PK), HeidelbergCement (HEI.DE), Henkel pref. (HEN3.DE), Human Genome Sciences (HGSI), IDT Corp. (IDT), Infineon (IFX.DE), KSB pref. (KSB3.DE), Lexicon Pharmaceuticals (LXRX), Mahindra Satyam (SAY), Petroleo Brasileiro (PBR), Porsche pref. (PAH3.DE), Qiagen (QGEN), Repsol (REP), SAP (SAP), Seabridge Gold (SA), Sequenom (SQNM), SourceForge (LNUX), Siemens (SI), Telefónica (TEF), TheStreet.com (TSCM), ThyssenKrupp (TKA.DE), Trident Microsystems (TRID), Unicredit (UCG.MI), VW pref. (VOW3.DE).

My by far largest position is EMC. I also hold plain vanilla calls on EMC.

Report this comment
#2) On October 09, 2009 at 3:04 AM, MDGiz (< 20) wrote:

My first post ever here!!  You are one of my favorites that I enjoy reading posts from.  Many others I just pass by...Other favs, GV and Dragon!  Those guys rock!!

Good picks, not too bad of returns.  Markets will be trading flat as "we" know in Europe for a while.  Waiting for "Big Brother" U.S.A. to pick up before Europe, BRIC and other emerging markets blow U.S.A. away on stock perfomance.  You are right to stay foreign fo now but boy "Gruss Gott" (sp?)you are biased in Germany!! At first I didnt see Bayer in there :), now I do!!

Tchuss!!

Giz

Report this comment
#3) On October 09, 2009 at 3:07 AM, Tastylunch (29.31) wrote:

Mahindra Saytam?

Interesting. Too messy for my tastes but there is a plausible value argument there.

I sold my stake in TRID, perhaps I got out too early on that one.

any thoughts on XING since youseem to be of the value persuasion?

Report this comment
#4) On October 09, 2009 at 3:43 AM, devilzadvocate (49.14) wrote:

I own SAY and PBR from this new list.

TRID looks very interesting.

IDT is coming up in OVERBOUGHT territory in both Stochastic Oscillator and RSI..

Report this comment
#5) On October 09, 2009 at 5:39 PM, portefeuille (99.60) wrote:

IDT is coming up in OVERBOUGHT territory in both Stochastic Oscillator and RSI..

I am not holding it for reasons of "technical analysis".

any thoughts on XING since youseem to be of the value persuasion?

No, I don't have any thoughts on XING. I am not sure I am a value investor, but I hope I am if you take a somewhat "liberal" interpretation. 

Report this comment
#6) On October 09, 2009 at 5:42 PM, portefeuille (99.60) wrote:

you are biased in Germany!!

Yes, good old "home bias". I am German. More calls are in this list. A recent "track record" is here.

Report this comment
#7) On October 09, 2009 at 5:54 PM, portefeuille (99.60) wrote:

If I were to buy shares next week it would be LXRX shares (they have by now "retraced the gap up" that was caused by these results, announced on 09/15/09.

-------------------------------------------------------------

Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes

- Lexicon's Fourth Drug Candidate in Phase 2 Development
- Oral Drug Candidate Inhibits SGLT2, a Potential Target for Diabetes
- Phase 1 Results Support Once Daily Dosing in Patients with Type 2 Diabetes

    * Press Release
    * Source: Lexicon Pharmaceuticals, Inc.
    * On 6:30 am EDT, Tuesday September 15, 2009

THE WOODLANDS, Texas, Sept. 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX - News), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon's fourth drug candidate currently being tested in Phase 2 clinical trials.

"LX4211 offers an opportunity to treat diabetes by increasing urinary glucose excretion through a mechanism of action that is expected to avoid some of the disadvantages of existing diabetes drugs that result in storage of excess glucose," said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer at Lexicon. "By contrast, LX4211 through inhibition of SGLT2 has the potential to reduce caloric load and thereby enhance overall glucose homeostasis in patients with type 2 diabetes."

In the recently completed Phase 1 clinical trial in normal healthy volunteers, LX4211 was well tolerated at all dose levels and produced a dose-dependent increase in urinary glucose excretion. LX4211 also demonstrated a favorable pharmacokinetic profile supporting the potential for once daily dosing. Adverse events were generally mild and were distributed across all dose groups, including the placebo group.

Based on the Phase 1 clinical results, Lexicon has initiated a Phase 2 clinical trial to evaluate the safety and tolerability of two dose levels of LX4211 and its effect on diabetes biomarkers including: fasting blood glucose, urinary glucose excretion and response to oral glucose tolerance testing in patients with type 2 diabetes. The four-week, randomized, double-blind, placebo-controlled study will be conducted in the United States and is expected to enroll 36 patients with type 2 diabetes.

In addition to LX4211, Lexicon has three other drug candidates progressing in Phase 2 clinical trials: LX1031 for irritable bowel syndrome, LX1032 for carcinoid syndrome and LX2931 for rheumatoid arthritis. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

About the Target

LX4211 was developed at Lexicon as a potent inhibitor of the sodium glucose transporter 2 (SGLT2), a transporter responsible for the majority of glucose reabsorption by the kidneys. Lexicon found that mouse knockouts engineered to lack the SGLT2 gene are healthy and require less insulin to manage a glucose challenge. Compounds developed by Lexicon that inhibit SGLT2 may potentially treat diabetes by increasing urinary glucose excretion, thereby lowering blood glucose levels as well as caloric load.

...

-------------------------------------------------------------

Report this comment
#8) On October 09, 2009 at 5:57 PM, Tastylunch (29.31) wrote:

portefeuille

 but I hope I am if you take a somewhat "liberal" interpretation

you are if you want to be. There are so many people who bastardized what it menat to be a value investor that the term is almost meaningless

you'll notice I didn't qualify what kind of "value" investor I thought you to be. :)

in any event I just regularly notice a fair amount of value style plays in your top picks.

I'm not sure what would I actually call you. You seem to look for mispricings, regardless of the casue (special situations, spinoffs opacity of business model etc)

Report this comment
#9) On October 09, 2009 at 6:05 PM, portefeuille (99.60) wrote:

You seem to look for mispricings, regardless of the casue (special situations, spinoffs opacity of business model etc)

yes, mispricings are great!

Report this comment
#10) On October 10, 2009 at 1:53 AM, portefeuille (99.60) wrote:

update (see this post)



enlarge

Report this comment
#11) On October 11, 2009 at 5:21 AM, portefeuille (99.60) wrote:

Bill Ackman's Latest Short Position (Hedge Fund Pershing Square)

Report this comment
#12) On October 11, 2009 at 5:30 AM, portefeuille (99.60) wrote:

Renaissance’s Simons Said to Retire From Hedge Fund

Renaissance CEO James Simons to retire: source

Report this comment
#13) On October 09, 2010 at 11:22 PM, portefeuille (99.60) wrote:

continued here.

Report this comment

Featured Broker Partners


Advertisement